financetom
Business
financetom
/
Business
/
Volkswagen pushing ahead with German cost-cutting, brand boss says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Volkswagen pushing ahead with German cost-cutting, brand boss says
Mar 10, 2026 10:50 PM

BERLIN, Dec 18 (Reuters) - Volkswagen is making progress with its cost-cutting drive, the head of the German carmaker's core brands said in a media interview on Thursday, pointing to headcount reductions and savings at the group's plants in Germany.

The company has reduced costs at its factories in Wolfsburg, Emden and Zwickau by 30% on average, brand CEO Thomas Schaefer told the Auto Motor Sport industry magazine.

On top of this, some 25,000 workers have signed partial retirement or severance agreements, he added.

"We still have a way to go, but together we want to prove that it is possible to develop and build competitive cars in Germany," Schaefer said.

In December 2024, Volkswagen struck an agreement with unions to drastically restructure its German operations, including 35,000 jobs cuts by 2030, as it faces off with cheaper Chinese rivals and navigates a slower-than-expected shift to electric.

On Tuesday, the European Commission dropped its hard cut-off for new combustion-engine cars from 2035, bowing to calls from Volkswagen and other carmakers for greater flexibility.

Schaefer ruled out offering combustion engines in the core brands' new small-car family, whose first model - the ID.Polo - is to be launched next year at a starting price of around 25,000 euros ($29,307.50).

This wouldn't make sense due to emissions regulations and would be too expensive for consumers, according to the executive.

"The future in this segment is electric," he said.

($1 = 0.8530 euros)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
First Nordic Metals Changes Its Name; Shares up 5.6%
First Nordic Metals Changes Its Name; Shares up 5.6%
Mar 10, 2026
12:59 PM EST, 12/22/2025 (MT Newswires) -- First Nordic Metals (FNM.V) on Monday said that, effective as of today's date, it has changed its name to Goldsky Resources Corp. The company said that its common shares are expected to begin trading under the new name and under the ticker 'GSKR' on the TSX Venture Exchange on Dec. 24, 2025. A...
Olo Completes Acquisition of Spendgo to Expand Platform with Loyalty Solution
Olo Completes Acquisition of Spendgo to Expand Platform with Loyalty Solution
Mar 10, 2026
Olo Loyalty will help restaurant brands drive repeat visits, deepen guest relationships, and drive more profitable traffic NEW YORK--(BUSINESS WIRE)-- Olo, the leading technology platform purpose-built for restaurants, today announced it has completed the acquisition of Spendgo, an industry-proven loyalty and guest engagement platform. Olo Loyalty will enable restaurant brands to enhance guest engagement and increase profitability alongside Olo's...
Vale Stock Is Surging Monday: What's Driving The Action?
Vale Stock Is Surging Monday: What's Driving The Action?
Mar 10, 2026
Vale SA ( VALE ) shares are rallying Monday afternoon amid a broader surge in precious metals stocks driven by fiscal deficits in major economies including the U.S., U.K. and China. Here’s what investors need to know. Vale shares are powering higher. Why is VALE stock up today? What To Know: While soaring gold prices have lifted the commodities sector,...
Why Wall Street Is Watching Immutep's Experimental Autoimmune Treatment Closely
Why Wall Street Is Watching Immutep's Experimental Autoimmune Treatment Closely
Mar 10, 2026
Immutep Limited ( IMMP ) on Monday shared an update from the placebo-controlled, double-blind first-in-human Phase I study in healthy participants evaluating IMP761, a first-in-class LAG-3 agonist antibody for autoimmune diseases. The single-ascending dose escalation portion of the trial completed the 2.5 and 7 mg/kg dosing levels of IMP761 with continued positive safety and efficacy data. IMP761 was tolerated well...
Copyright 2023-2026 - www.financetom.com All Rights Reserved